MedPath

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain, for AADC Deficiency

• The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in both children and adults, addressing the full spectrum of disease severity. • Kebilidi is the first gene therapy approved in the U.S. that is directly administered to the brain, offering a novel approach to treating this rare neurological disorder. • This gene replacement therapy restores dopamine synthesis in the brain by delivering it directly to the putamen, improving motor development in patients with AADC deficiency. • The approval is based on clinical trial data, with ongoing studies to confirm the therapy's long-term effects; Kebilidi was previously approved in the EU and UK as Upstaza.

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. This marks the first gene therapy to be directly administered to the brain to receive FDA approval.
AADC deficiency is a rare genetic disorder caused by mutations in the DDC gene, which encodes the AADC enzyme. This enzyme is crucial for the production of neurotransmitters like dopamine and serotonin. Deficiency leads to impaired motor function, developmental delays, and autonomic nervous system dysfunction.

Mechanism of Action

Kebilidi functions as a gene replacement therapy. It is administered directly into the putamen, a region in the brain, via a minimally invasive neurosurgical procedure. The therapy delivers a functional copy of the DDC gene, restoring dopamine synthesis in the brain and improving motor development.

Clinical Evidence

The FDA's approval is based on data from an ongoing clinical trial. This trial aims to provide confirmatory evidence regarding the long-term effects of Kebilidi. The therapy has already been approved in the European Union in 2022 and in the United Kingdom in 2023, where it is marketed as Upstaza.

Company Insights

PTC Therapeutics, a biopharmaceutical company headquartered in Mountain View, California, is responsible for bringing Kebilidi to market in the US. PTC Therapeutics acquired Agilis Biotherapeutics, the original developer of Kebilidi, in August 2018. According to Matthew B. Klein, CEO of PTC Therapeutics, this approval represents a pioneering approach to treating highly morbid neurologic diseases, and he expressed pride in his team's commitment to achieving this regulatory milestone.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves First Brain-Injected Gene Therapy Kebilidi for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, the first of its kind to be injected directly into the brain.
Kebilidi is designed to boost AADC enzyme production in the brain, restoring dopamine levels and improving motor function in children and adults with the rare genetic disorder.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the U.S.
Kebilidi is administered directly into the brain and replaces the mutated DDC gene with a functional version, restoring dopamine and serotonin production in both adults and children.

FDA Approves PTC Therapeutics' Upstaza for AADC Deficiency

The FDA has approved Upstaza (eladocagene exuparvovec), a gene therapy developed by PTC Therapeutics, for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency.
Upstaza is administered directly into the brain via neurosurgical procedure, offering a novel approach to address the underlying genetic defect of AADC deficiency.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first such treatment approved in the U.S.
Kebilidi delivers a functional copy of the DDC gene to brain cells, restoring the missing AADC enzyme and enabling dopamine production in both children and adults.

FDA Approves KEBILIDI, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved KEBILIDI (eladocagene exuparvovec-tneq), a gene therapy for aromatic l-amino acid decarboxylase (AADC) deficiency, marking the first brain-delivered gene therapy in the U.S.
KEBILIDI, developed by PTC Therapeutics, is a gene replacement therapy administered directly to the brain to restore dopamine production in patients with AADC deficiency.

FDA Approves PTC Therapeutics' Kebilidi for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency, a rare genetic disorder.
Kebilidi is a gene therapy designed to deliver a functioning DDC gene directly into the putamen to enhance the AADC enzyme and restore dopamine production.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the US.
Kebilidi replaces the mutated DDC gene, enabling dopamine synthesis and addressing severe motor and neurological symptoms in children and adults with AADC deficiency.

FDA Approves PTC Therapeutics' Gene Therapy KEBILIDI for AADC Deficiency

The FDA has granted accelerated approval to KEBILIDI (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first FDA-approved gene therapy directly administered to the brain.
KEBILIDI, developed by PTC Therapeutics, is indicated for both children and adults with AADC deficiency, addressing a critical unmet need across the spectrum of disease severity.

FDA Approves Kebilidi Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in both children and adults.
Kebilidi, a gene replacement therapy, is administered directly into the brain to restore dopamine production, addressing the underlying genetic defect.

Reference News

[1]
FDA approves first-ever gene therapy to be directly administered to the ...
biopharma-reporter.com · Nov 19, 2024

FDA approved Kebilidi, a gene therapy for AADC deficiency, marking the first US-approved brain-administered treatment. I...

[2]
FDA approves first-ever gene therapy to be directly administered to the brain
biopharma-reporter.com · Nov 19, 2024

The FDA approved Kebilidi (eladocagene exuparvovec-tneq) for AADC deficiency, making it the first brain-administered the...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy